Quoin Pharmaceuticals, Ltd. (QNRX)
- Previous Close
6.41 - Open
6.27 - Bid --
- Ask --
- Day's Range
6.20 - 6.34 - 52 Week Range
5.01 - 54.95 - Volume
4,345 - Avg. Volume
207,320 - Market Cap (intraday)
3.705M - Beta (5Y Monthly) 1.60
- PE Ratio (TTM)
-- - EPS (TTM)
-66.85 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
156.80
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
quoinpharma.comRecent News: QNRX
View More
Performance Overview: QNRX
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: QNRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: QNRX
View MoreValuation Measures
Market Cap
3.68M
Enterprise Value
-10.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.40
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.72%
Return on Equity (ttm)
-120.55%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-8.96M
Diluted EPS (ttm)
-66.85
Balance Sheet and Cash Flow
Total Cash (mrq)
14.06M
Total Debt/Equity (mrq)
31.76%
Levered Free Cash Flow (ttm)
-4.28M